FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD‐L1 Expression and Cell Proliferation
Open Access
- 17 August 2022
- journal article
- research article
- Published by Wiley in Advanced Science
- Vol. 9 (29) , e2202702
Abstract
Programmed death‐ligand 1 (PD‐L1) is a major target to cancer immunotherapy, and anti‐PD‐L1 and anti‐PD‐1 antibody‐mediated immunotherapy are being increasingly used. However, immune checkpoint inhibitors (ICIs) are ineffective in treating large tumors and cause various immune‐related adverse events in nontarget organs, including life‐threatening cardiotoxicity. Therefore, the development of new therapeutic strategies to overcome these limitations is crucial. The focus of this study is the forkhead box protein M1 (FOXM1), which is identified as a potential therapeutic target for cancer immunotherapy and is associated with the modulation of PD‐L1 expression. Selective small interfering RNA knockdown of FOXM1 or treatment with thiostrepton (TST) significantly reduces PD‐L1 expression in non‐small‐cell lung cancer (NSCLC) cells and inhibits proliferation. Chromatin immunoprecipitation‐PCR reveals that FOXM1 selectively upregulates PD‐L1 expression by binding directly to the PD‐L1 promoter. In vivo animal studies have shown that TST treatment significantly downregulates PD‐L1 expression in human NSCLC tumors, while greatly reducing tumor size without side effects on normal tissues. Combined treatment with TST and anti‐4‐1BB antibody in the LLC‐1 syngeneic tumor model induces synergistic therapeutic outcomes against immune resistant lung tumors as well as 2.72‐folds higher CD3+ T cells in tumor tissues compared to that in the anti‐4‐1BB antibody treatment group.Keywords
Funding Information
- National Cancer Center (2210721, 2110540)
This publication has 46 references indexed in Scilit:
- The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing’s sarcomaInternational Journal of Oncology, 2013
- Enrichr: interactive and collaborative HTML5 gene list enrichment analysis toolBMC Bioinformatics, 2013
- FoxM1 Is Associated with Poor Prognosis of Non-Small Cell Lung Cancer Patients through Promoting Tumor MetastasisPLOS ONE, 2013
- Thiazole Antibiotics Siomycin a and Thiostrepton Inhibit the Transcriptional Activity of FOXM1Frontiers in Oncology, 2013
- Primer3—new capabilities and interfacesNucleic Acids Research, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- FoxM1 Promotes β-Catenin Nuclear Localization and Controls Wnt Target-Gene Expression and Glioma TumorigenesisCancer Cell, 2011
- Evaluating the Cellular Targets of Anti-4-1BB Agonist Antibody during Immunotherapy of a Pre-Established Tumor in MicePLOS ONE, 2010
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and SurvivorshipMayo Clinic Proceedings, 2008
- PD‐1 inhibits T‐cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθFEBS Letters, 2004